HARP(Delisted)
Harpoon TherapeuticsยทNASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About HARP
Harpoon Therapeutics, Inc.
A clinical-stage immunotherapy company that developing a novel class of T cell to treat cancer and other diseases
131 Oyster Point Blvd, Suite 300 , South San Francisco, CA 94080
--
Harpoon Therapeutics, Inc., was incorporated in Delaware in March 2015. They are a clinical-stage immunotherapy company developing a new type of T-cell participant that harnesses the power of the human immune system to treat patients with cancer and other diseases. Using their proprietary Tri-specific T cell activation constructs, or TriTAC platform, they are developing a pipeline of new T cell participants, or TriTACs, initially focused on the treatment of solid tumors and hematological malignancies. Since starting operations in 2015, they have created four TriTAC product candidates, and they expect to have four TriTACs for clinical development by the end of 2020.
Company Financials
EPS
HARP has released its 2023 Q3 earnings. EPS was reported at -0.46, versus the expected -3.2, beating expectations. The chart below visualizes how HARP has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
HARP has released its 2023 Q3 earnings report, with revenue of 4.45M, reflecting a YoY change of -67.33%, and net profit of -1.80M, showing a YoY change of 84.52%. The Sankey diagram below clearly presents HARP's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
No Data
You can ask Aime
No Data
